ArticlemBio2020
Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?
Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04475081 (Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis/Inflammation), which is not on this map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis/Inflammation
Who cites it
63 citing papers in PubMed, 115 citations in OpenAlex.
- Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial.Frontiers in immunology · 2022Trial
- Innovations, Challenges, and Future Prospects for Combination Vaccines Against Human Infections.Vaccines · 2025Review
- Age-dependent ACE2/TMPRSS2 expression and SARS-CoV-2 household transmission in Gran Canaria.PloS one · 2025Observational
- Low Rates of Immunity among Medical Students and Residents in the Era of the Resurgence of Measles.Pathogens (Basel, Switzerland) · 2024Article
- SIR+ models: accounting for interaction-dependent disease susceptibility in the planning of public health interventions.Scientific reports · 2024Article
- Clinical Characteristics, Diagnosis, and Therapeutics of COVID-19: A Review.Current medical science · 2023Review
- Measles vaccine uptake among Italian medical students compared to the pre-COVID-19 era.Human vaccines & immunotherapeutics · 2023Observational
- Are Measles-Mumps-Rubella (MMR) Antibodies Friends or Foes for Covid-19 Disease?Archivum immunologiae et therapiae experimentalis · 2023Article
- The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups.Pathogens (Basel, Switzerland) · 2023Review
- Effect of MMR Vaccination to Mitigate Severe Sequelae Associated With COVID-19: Challenges and Lessons Learned.Medical research archives · 2023Article
- Crosslink between SARS-CoV-2 replication and cystic fibrosis hallmarks.Frontiers in microbiology · 2023Review
- Beneficial non-specific effects of live vaccines against COVID-19 and other unrelated infections.The Lancet. Infectious diseases · 2023Review
- Review
- Influenza Vaccine and COVID-19 Pandemic: Could This Vaccine Help Limit the Potential Adverse Consequences of SARS-CoV-2?Iranian journal of pharmaceutical research : IJPR · 2022Article
- Recent advances in the vaccine development for the prophylaxis of SARS Covid-19.International immunopharmacology · 2022Review
- Does the rubella immunoglobulin G affect the severity of COVID- 19? : Rubella immunoglobulin G and COVID- 19.BMC microbiology · 2022Article
- Knowledge and Practice of Parents Towards Measles, Mumps and Rubella Vaccination.The Malaysian journal of medical sciences : MJMS · 2022Article
- COVID-19 susceptibility and vaccination coverage for measles, rubella and mumps in students and healthcare workers in Trieste hospitals (NE Italy).Vaccine: X · 2022Article
- Recent Update of COVID-19 Vaccines.Advanced pharmaceutical bulletin · 2022Review
- Why Does the Severity of COVID-19 Differ With Age?: Understanding the Mechanisms Underlying the Age Gradient in Outcome Following SARS-CoV-2 Infection.The Pediatric infectious disease journal · 2022Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
We propose the concept that administration of an unrelated live attenuated vaccine, such as MMR (measles, mumps, rubella), could serve as a preventive measure against the worst sequelae of coronavirus disease 2019 (COVID-19). There is mounting evidence that live attenuated vaccines provide nonspecific protection against lethal infections unrelated to the target pathogen of the vaccine by inducing "trained" nonspecific innate immune cells for improved host responses against subsequent infections. Mortality in COVID-19 cases is strongly associated with progressive lung inflammation and eventual sepsis. Vaccination with MMR in immunocompetent individuals has no contraindications and may be especially effective for health care workers who can easily be exposed to COVID-19. Following the lead of other countries conducting clinical trials with the live attenuated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.